Current and emerging applications of fluorine in medicinal chemistry

Fluorinated Pharmaceuticals: Advances in Medicinal Chemistry

Volumn , Issue , 2015, Pages 126-139

  Perrone, Maria Grazia ^a   Vitale, Paola ^a   Panella, Andrea ^b   Tolomeo, Anna ^c   Scilimati, Antonio ^d  

^a UNIVERSITY OF BARI   (Italy)

^b Medical School Department of Biological Chemistry   (United States)

^c ITEL TELECOMUNICAZIONI   (Italy)

^d UNIVERSITY OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84953786182     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.2217/9781909453968.FSEB2013.13.113     Document Type: Chapter

References (19)

1. Petrov VA. Fluorinated Heterocyclic Compounds: Synthesis, Chemistry, and Applications., Germany, Hoboken, Wiley (2009).
2. Gardiner IV. (Ed.) Fluorine Chemistry Research Advances. Nova Publishers, NY, USA (2007).
3. Takeru F, Kuttruff CA, Ritter T. Carbon-fluorine bond formation. Curr. Opin. Drug Discov. Devel. 11, 803-819 (2008).
4. Jin Z, Hammond GB, Xu B. Aldrichim. Acta 45, 67-83 (2012), Dijkgraaf I, Franssen GM, McBride WJ, et al. Transitional metal sponsored fluorinated, difluoromethylation and trifluoromethylation. J. Nucl. Med. 53, 947-952 (2012).
5. Dijkgraaf I, Franssen GM, McBride WJ, et al. Transitional metal sponsored fluorinated, difluoromethylation and trifluoromethylation. J. Nucl. Med. 53, 947-952 (2012).
6. Shibata N, Matsnev A, Beilstein CD. Shelf-stable electrophilic trifluoromethylating reagents: a brief historical perspective. J. Org. Chem. 6, 1-19 (2010).
7. Perrone MG, Malerba P, Uddin MdJ et al. [18F]-P6 analogue as PET imaging agent targeting Cyclooxygenase-1. Europ. J. Med. Chem. 80, 562-568 (2014).
8. Karlheinz D, Groger H, May O. Enzyme catalysis in organic synthesis. Wiley-VHC VerlagGmBH, Weinheim-Germany, (2012).
9. Eustáquio AS, O'Hagan D, Moore BS. Engineering fluorometabolite production: fluorinase expression in Salinispora tropica yields fluorosalinosporamide J. Nat. Prod. 73, 378-382 (2010).
10. Patani GA, LaVoie EJ. Bioisosterism: a rational approach in drug design. Chem. Rev. 96, 3147-3176, (1996).
11. Perrone MG, Contino M, Scilimati A. Exploring prospects of 133-adrenoceptor agonists and inverse agonists for colon motility control. Drugs and Therapy Studies 3 (e5), 20-23 (2013).
12. Perrone MG, Santandrea E, Bleve L et al. Stereospecific synthesis and bio-activity of novel 133-adrenoceptor agonists and inverse agonists. Bioorg. Med. Chem. 16, 2473-2488 (2008).
13. Kier LB. Bioisosterism: quantitation of structure and property effects. Chem. Biodiver. 1, 138-151 (2004).
14. Park BK, Kitteringham NR, O'Neill PM. Metabolism of fluorine containing drugs. Annu. Rev. Pharmacol. Toxicol. 41, 443-470 (2001).
15. Earl J, Kirkpatrick P. Ezetimibe. Nat. Rev. Drug Discov. 2, 97-98 (2003).
16. Dijkgraaf I, Franssen GM, McBride WJ et al. PET of tumors expressing gastrin-releasing peptide receptor with an 18F-labeled Bombesin Analog. J. Nucl. Med. 53, 947-952 (2012).
17. McBride WJ, D'Souza CA, Karacay H et al. New lyophilized kit for rapid radiofluorination of peptides. Bioconjug. Chem. 23, 538-547 (2012).
18. Merkel L, Budisa N. Organic fluorine as a polypepdtide building element: in vivo expression of fluorinated peptides, proteins and proteomes. Org. Biomol. Chem. 10, 7241-7261 (2012).
19. Hagmann W.K.. The many roles for fluorine in medicinal chemistry. J. Med. Chem. 51, 4359-4369 (2008).